Docket-Specific Pre-Screen
What we confirm before every Ozempic lead is delivered
- GLP-1 drug use confirmed — Ozempic, Wegovy, Mounjaro, Trulicity, or Victoza.
- Condition being treated documented — type 2 diabetes or weight management.
- Qualifying injury confirmed — gastroparesis, intestinal obstruction, ileus, severe nausea/vomiting with hospitalization, or vision loss.
- Hospitalization or ER treatment for GI complications confirmed and documented.
- Medical records referenced — GI specialist, treating physician, or hospital discharge summaries.
- Diagnosis timeline established — GI injury developed during or after GLP-1 use.
- SOL analyzed under discovery rule per diagnosis state.
- Not currently represented — confirmed before the lead leaves our system.
SOL Note
Ozempic/GLP-1 litigation SOL follows the discovery rule — it runs from when the claimant knew or should have known of the connection between the drug and their GI injury. The 2023 FDA label update including ileus is a reference point for awareness.
The Market
The Ozempic market
GLP-1 agonist drugs — including Ozempic, Wegovy, Mounjaro, Trulicity, and Victoza — face growing litigation over severe gastrointestinal complications. The FDA updated the Ozempic label in September 2023 to include ileus (intestinal paralysis) as a known side effect after reviewing adverse event reports. Other GI complications linked to the drug class include gastroparesis (stomach paralysis), intestinal obstruction, and severe recurrent vomiting requiring hospitalization.
The claimant population is patients who used GLP-1 drugs for diabetes or weight management and experienced severe GI complications requiring hospitalization. The litigation targets the manufacturers on failure-to-warn theories — the complication was known before the label was updated but not adequately disclosed to prescribers and patients.
This is a rapidly growing docket. Early case acquisition has meaningful value because the claimant population is expanding as Wegovy and Mounjaro use grows for weight loss indications. Our pre-screen confirms the specific GI complication and the hospitalization requirement before delivery — minor GI upset is not part of the qualifying population.
Docket Pipeline
How Ozempic leads are qualified
Targeted Acquisition
Only people who matched your exact criteria submitted a form.
Form Pre-Screen
SOL, liability, insurance, and intent — all confirmed before delivery.
Ozempic pre-screen confirms GLP-1 drug use and severe GI complication requiring hospitalization.
OTP Phone Verification
The number is real. We proved it before you see it.
Exclusive Delivery
Your CRM. One firm. In under 15 seconds.
Pricing is per qualified lead — never a retainer, never a setup fee, never a monthly commitment. Calculate your all-in cost per signed retainer before you book the call.
Delivery Standards
How every lead arrives and what stands behind it
Every lead passes through four verification steps before delivery. Targeted acquisition drives intake traffic only from people who match your stated criteria. The form pre-screen documents SOL, liability, injury severity, and representation status. OTP phone verification confirms the number is real, active, and in possession of the claimant — not Google Voice, not a disconnected line, not a wrong number. Exclusive delivery places the lead into your CRM inside 15 seconds, locked to your firm ID with a permanent delivery timestamp.
Exclusivity is contractual, not verbal. Your client agreement contains a binding exclusivity term — every lead is sold to exactly one firm and there is no operational path for us to re-deliver it. TrustedForm certificates and Jornaya lead IDs travel with every lead as an independent consent audit trail, timestamped outside our own delivery system. The 48-hour credit exchange is written into your agreement as a contract term, not a return policy: expired SOL at delivery, liability that clearly does not hold based on pre-screen facts, case type mismatch, or represented-at-delivery all qualify without additional documentation. Your intake team’s assessment is sufficient.
Coverage runs in 38 states. Pricing is per qualified lead — no retainer, no setup fee, no monthly commitment. Volume can be paused or reduced with 30 days notice without penalty. Auto-connect puts your intake team on the phone with the claimant within 60 seconds of delivery, which is the single largest lever on contact-to-signed-retainer conversion in every vendor benchmark we have run. Firms routinely report 18–23% close rates on identical leads simply by moving first-call contact from 5 minutes to 60 seconds.
Read the full pipeline breakdown for operational detail on each verification step, or run your numbers with the cost-per-retainer calculator before booking a call.
Frequently Asked Questions
- Ozempic leads are priced at $600 per qualified lead as a high-demand emerging docket. No retainer. No setup fee.
Related dockets
The Arrangement
No retainer. No setup fee. No monthly commitment.
Start receiving verified leads in 5–7 days. One firm per case. Every lead OTP-verified. Credit exchange written into your client agreement.